close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Peptilogics

News headline image
Former President of DePuy Synthes U.S. Joins Peptilogics Board
From Peptilogics
Via Business Wire
News headline image
Peptilogics Begins Pivotal Trial of First-Ever Drug Designed to Cure Medical Device-Related Infections
From Peptilogics
Via Business Wire
News headline image
Peptilogics Reports Positive 180-Day Top-Line Interim Data From Phase 1B Trial of PLG0206 in Patients With Periprosthetic Joint Infection (PJI)
From Peptilogics
Via Business Wire
News headline image
Peptilogics Reports Positive 90-Day Top Line Interim Data From Phase 1b Trial of PLG0206 in Patients With Periprosthetic Joint Infection (PJI)
From Peptilogics
Via Business Wire
News headline image
Peptilogics Completes Phase 1b Trial Enrollment and Will Present Interim Top-line Safety and Tolerability Data of PLG0206 in Patients Undergoing DAIR for the Treatment of Periprosthetic Joint Infection After a Total Knee Arthroplasty at ECCMID 2023
From Peptilogics
Via Business Wire
News headline image
Peptilogics Hosting Panel Discussion with Leading Industry Experts on the High Unmet Medical Need and Opportunity in Periprosthetic Joint Infections (PJI)
From Peptilogics
Via Business Wire
News headline image
Peptilogics to Present Data at IDWeek 2022 on PLG0206, an Engineered Antimicrobial Peptide Targeting Bacteria Causing Periprosthetic Joint Infection
From Peptilogics
Via Business Wire
News headline image
Peptilogics Presents Data Demonstrating Antimicrobial Activity Against Difficult to Treat Bacterial Pathogens of Engineered Peptide PLG0206 at the 2022 ASM/ESCMID Joint Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance
From Peptilogics
Via Business Wire
News headline image
Peptilogics Announces First Patient Dosed in Phase 1b Study of PLG0206 for Periprosthetic Joint Infection
From Peptilogics
Via Business Wire
News headline image
EpiAxis Therapeutics & Peptilogics Enter Strategic Drug Discovery Partnership
From Peptilogics
Via Business Wire
News headline image
Peptilogics Strengthens Leadership Team with Executive Appointments
From Peptilogics
Via Business Wire
News headline image
Peptilogics to Participate in Musculoskeletal Infection Society (MSIS) 32nd Annual Open Scientific Meeting in Pittsburgh
From Peptilogics
Via Business Wire
News headline image
Peptilogics Receives FDA Fast Track Designation for PLG0206, an Investigational Peptide Therapeutic in Development for the Treatment of Periprosthetic Joint Infection
From Peptilogics
Via Business Wire
News headline image
Orion Biotechnology and Peptilogics Enter Strategic Research Collaboration to Enable AI-Driven Drug Discovery Against Undrugged GPCR Target
From Peptilogics
Via Business Wire
News headline image
Peptilogics to Present Data Highlighting Designed Antimicrobial Peptide for the Treatment of Periprosthetic Joint Infection (PJI) at ECCMID 2022
From Peptilogics
Via Business Wire
News headline image
Peptilogics’ Presentations at American Academy of Orthopedic Surgeons (AAOS) 2022 Annual Meeting Highlight Peptide Therapeutic PLG0206 for the Treatment of Periprosthetic Joint Infection (PJI)
From Peptilogics
Via Business Wire
News headline image
Peptilogics Promotes Nicholas Nystrom, Ph.D., to Chief Technology Officer
From Peptilogics
Via Business Wire
News headline image
Peptilogics Announces FDA Clearance of Investigational New Drug Application to Initiate Clinical Trial of PLG0206 in Periprosthetic Joint Infection
From Peptilogics
Via Business Wire
News headline image
Peptilogics Receives Award from the Cystic Fibrosis Foundation to Investigate PLG0301 and PLG0206 as Potential Dual-Acting Treatments for Lung Infections Associated with Cystic Fibrosis
From Peptilogics
Via Business Wire
News headline image
Peptilogics Announces Two Peer-Reviewed Publications on Designed Peptide Therapeutic PLG0206 for Periprosthetic Joint Infection
From Peptilogics
Via Business Wire
News headline image
Peptilogics Presents Positive First-in-Human Phase 1 Data for its Lead Engineered Antibacterial Peptide, PLG0206, at IDWeek 2021
From Peptilogics
Via Business Wire
News headline image
Peptilogics to Present First-in-Human Phase 1 Clinical Data of PLG0206 at IDWeek 2021
From Peptilogics
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at /week.